Trastuzumab and ECG Changes Dilemma

Affiliations

¹ Cardio-Oncology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Science, Tehran, Iran.
² Department of Internal Medicine, Hematology and Medical Oncology Ward, Cancer Research Center, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.

Editorial

Azin Alizadehasl et al. Int J Hematol Oncol Stem Cell Res. 2023.

. 2023 Apr 1;17(2):63-64.

doi: 10.18502/ijhoscr.v17i2.12641.

¹ Cardio-Oncology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Science, Tehran, Iran.
² Department of Internal Medicine, Hematology and Medical Oncology Ward, Cancer Research Center, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.

No abstract available

References

1. Anjos M, Fontes-Oliveira M, Costa VM, et al. An update of the molecular mechanisms underlying doxorubicin plus trastuzumab induced cardiotoxicity. Life Sci. 2021;280:119760. - PubMed
1. Olorundare OE, Adeneye AA, Akinsola AO, et al. Therapeutic Potentials of Selected Antihypertensive Agents and Their Fixed-Dose Combinations Against Trastuzumab-Mediated Cardiotoxicity. Front Pharmacol. 2021;11:610331. - PMC - PubMed
1. Vazdar L, Gabric ID, Kruljac I, et al. Influence of Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in early-stage HER2 positive breast cancer. Sci Rep. 2021;11(1):14395. - PMC - PubMed
1. Elme A, Saarto T, Totterman KJ, et al. Electrocardiography changes during adjuvant breast cancer therapy: incidence and risk factors. Anticancer Res. 2013;33(11):4933–9. - PubMed
1. Piotrowski G, Gawor R, Stasiak A, et al. Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 - a prospective study. Arch Med Sci. 2012;8(2):227–35. - PMC - PubMed